Incyte Corporation INCY
Super Investor & Insider
2
Fondi che lo detengono
#409
Rank consenso
2.9%
% dei portafogli
$1.23B
Valore detenuto
| Fondo | % portaf. | Attività | Azioni | Valore |
|---|---|---|---|---|
| Dodge & Cox · Dodge & Cox | 0.63% | Reduce 7.61% | 12,252,356 | $1.15B |
| Harry Burn · Sound Shore Management | 2.42% | Reduce 17.42% | 767,829 | $72.3M |
Fondi: 13F-HR alla SEC. Insider: acquisti (P) e vendite (S) in borsa da SEC EDGAR, ultimi 12 mesi.
About
Incyte Corporation is a biopharmaceutical company that focuses on the discovery, development, and commercialization of proprietary therapeutics for serious medical conditions. The company concentrates on hematology and oncology, as well as inflammation, autoimmunity, and dermatology, addressing diseases with significan…
SectorHealthcare
ExchangeNASDAQ
IndustryBiotechnology
CountryUnited States
Employees2,844
TickerINCY
Statistics
Market Cap$19.85B
Revenue (TTM)$5.14B
Net Income$1.29B
Net Margin25.0%
EPS$6.41
P/E15.23
P/S4.02
P/B3.83
EV/EBITDA11.03
ROE30.8%
Dividend Yield—
Price$99.27
Data: Twelve Data · Revenue = mcap / P/S